<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zheng X</submitter><funding>National Natural Science Foundation of China</funding><pagination>E279</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5872697</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(3)</volume><pubmed_abstract>Thyroid cancer (TC) is the most common endocrine malignancy without reliable preventive agent. Resveratrol possesses in vitro anti-TC activities; while its effect(s) on thyroid tumorigenesis remains unknown. This study aims to address this issue using DEN/MNU/DHPN-induced rat carcinogenesis model. 50 male Sprague-Dawley rats were separated into four groups as Group-1 (5 rats); normally fed; Group-2 (15 rats); DEN/MNU/DHPN treatment only; Group-3 (15 rats) and -4 (15 rats); DEN/MNU/DHPN treatment; followed by resveratrol intragastric (IG) injection and intraperitoneal (IP) injection; respectively; in two-day intervals for 30 weeks. The results revealed that the average resveratrol concentration in thyroid tissues was 1.278 ± 0.419 nmol/g in IG group and 1.752 ± 0.398 nmol/g in IP group. The final body weights of Group-3 and Group-4 were lighter than that (&lt;i>p&lt;/i> > 0.05) of Group-1; but heavier than Group-2 (&lt;i>p&lt;/i> &lt; 0.05). TC-related lesions (hyperplasia and adenomas) were found in 53.3% of Group-2; 33.3% Group-3 and 26.7% Group-4. Lower serum carcino-embryonic antigen (CEA) and thyroglobulin (Tg) levels; down-regulated expression of IL-6 and cyclooxygenase-2 (COX-2); reduction of NF-κB/p65 nuclear translocation; and elevated IkB&lt;i>α&lt;/i> expression were found in the thyroid tissues of Group-3 and Group-4 in comparison with that of Group-2. These results demonstrate that IG and IP administered resveratrol efficiently reduces the frequency and severity of DEN/MNU/DHPN-caused TC-related lesions and would be of values in thyroid tumor prevention.</pubmed_abstract><journal>Nutrients</journal><pubmed_title>Preventive Potential of Resveratrol in Carcinogen-Induced Rat Thyroid Tumorigenesis.</pubmed_title><pmcid>PMC5872697</pmcid><funding_grant_id>81672945</funding_grant_id><funding_grant_id>81272786</funding_grant_id><funding_grant_id>81450016</funding_grant_id><pubmed_authors>Kong QY</pubmed_authors><pubmed_authors>Li H</pubmed_authors><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Zheng X</pubmed_authors><pubmed_authors>Qiu ZW</pubmed_authors><pubmed_authors>Jia B</pubmed_authors><pubmed_authors>Song X</pubmed_authors><pubmed_authors>Wu ML</pubmed_authors></additional><is_claimable>false</is_claimable><name>Preventive Potential of Resveratrol in Carcinogen-Induced Rat Thyroid Tumorigenesis.</name><description>Thyroid cancer (TC) is the most common endocrine malignancy without reliable preventive agent. Resveratrol possesses in vitro anti-TC activities; while its effect(s) on thyroid tumorigenesis remains unknown. This study aims to address this issue using DEN/MNU/DHPN-induced rat carcinogenesis model. 50 male Sprague-Dawley rats were separated into four groups as Group-1 (5 rats); normally fed; Group-2 (15 rats); DEN/MNU/DHPN treatment only; Group-3 (15 rats) and -4 (15 rats); DEN/MNU/DHPN treatment; followed by resveratrol intragastric (IG) injection and intraperitoneal (IP) injection; respectively; in two-day intervals for 30 weeks. The results revealed that the average resveratrol concentration in thyroid tissues was 1.278 ± 0.419 nmol/g in IG group and 1.752 ± 0.398 nmol/g in IP group. The final body weights of Group-3 and Group-4 were lighter than that (&lt;i>p&lt;/i> > 0.05) of Group-1; but heavier than Group-2 (&lt;i>p&lt;/i> &lt; 0.05). TC-related lesions (hyperplasia and adenomas) were found in 53.3% of Group-2; 33.3% Group-3 and 26.7% Group-4. Lower serum carcino-embryonic antigen (CEA) and thyroglobulin (Tg) levels; down-regulated expression of IL-6 and cyclooxygenase-2 (COX-2); reduction of NF-κB/p65 nuclear translocation; and elevated IkB&lt;i>α&lt;/i> expression were found in the thyroid tissues of Group-3 and Group-4 in comparison with that of Group-2. These results demonstrate that IG and IP administered resveratrol efficiently reduces the frequency and severity of DEN/MNU/DHPN-caused TC-related lesions and would be of values in thyroid tumor prevention.</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Feb</publication><modification>2024-10-18T07:31:45.592Z</modification><creation>2019-03-26T23:20:56Z</creation></dates><accession>S-EPMC5872697</accession><cross_references><pubmed>29495605</pubmed><doi>10.3390/nu10030279</doi></cross_references></HashMap>